Toronto, Ontario – TheNewswire - 5 September 2025 – Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announced today that it has elected not to proceed with the previously announced equity draw-down subscription facility with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (together, “GEM”). The Company entered into a non-binding term sheet dated O ...

融资活动 - 公司完成非经纪私募配售 发行2,222,333股普通股 每股价格0.75加元 募集资金总额1,666,750加元 [1] - 此次私募是桥接融资策略的第二阶段 此前于2025年1月9日完成300万加元私募 [2] - 配售股份需遵守四个月零一天禁售期 至2025年12月23日到期 同时支付中介费用给合格介绍人 [2] - 公司计划在获得多伦多交易所新价格保护批准后启动下一轮私募 [1] 资金用途与战略规划 - 净收益将用于近期研发活动及营运资金需求 [2] - 正与机构投资者进行积极建设性讨论 预计达成更大规模融资以支持长期战略计划及纳斯达克升级上市 [2] 产品管线 - 主导产品L-DOS47为临床阶段抗体-酶结合物 针对CEACAM6表达肿瘤 已完成非小细胞肺癌Ib期研究 [5] - 新一代双特异性抗体药物偶联物处于发现阶段 共享CEACAM6靶向基础 [5] - 两个临床前候选药物：口服免疫检查点调节剂LEUMUNA针对移植后白血病复发 口服吉西他滨前药GEMCEDA生物利用度与静脉注射相当 [5] 公司概况 - 临床阶段肿瘤学公司 专注于难治性癌症治疗方案 [1] - 普通股在多伦多交易所(代码HBP) 美国场外市场(代码HBPCF) 法兰克福交易所(代码HBP0)挂牌交易 [6]

Toronto, Ontario – TheNewswire - 13 August 2025 – Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announced today the publication of a peer-reviewed article in Frontiers in Oncology titled "Safety of unconventional antibody-drug conjugate L-DOS47 in a Phase I/II monotherapy study targeting advanced NSCLC". The publication reports results from a previo ...